In the News

Posted on February 28, 2012
IIPM Associate Director Bryan Schneider, MD: 2012 Forty Under 40
Dr. Bryan Schneider is an associate professor of medicine at the Indiana University Melvin and Bren Simon Cancer Center. He holds appointments in the Divisions of Hematology/Oncology and Clinical Pharmacology in the Department of Medicine with a secondary appointment in the Department of Medical and Molecular Genetics. He is a recipient of the prestigious Komen Promise Award and his achievements in breast cancer research have earned him a spot on this year's celebrated IBJ Forty Under 40 list. Read his full story and watch the interview online at the Indianapolis Business Journal.

Cocktail of Popular Drugs May Cloud Brain
The New York Time Health Blog
Many people are unaware that dozens of painkillers, antihistamines and psychiatric medications — from drugstore staples to popular antidepressants — can adversely affect brain function, mostly in the elderly. Regular use of multiple medications that have this effect has been linked to cognitive impairment and memory loss. Read more...

From Indianapolis Discovery Network for Dementia (IDND)
To assist with the recognition of these medications, Dr. Malaz A. Boustani and an interdisciplinary team developed the Anticholinergic Cognitive Burden (ACB) list as a practical tool that identifies the severity of anticholinergic effects on cognition of both prescription and over-the-counter medications. Read more...

Posted on September 27, 2011
National Institute of Child Health & Human Development U54 Grant Award
NICHD U54 Grant awarded to Drs. Jamie Renbarger and David Flockhart! Project Title: Indiana University Center for Pediatric Pharmacology.

Posted on September 16, 2011
2011 ACRA Awarded to Bryan P. Schneider, MD

Bryan Paul Schneider, MD

The Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO) (formerly The ASCO Cancer Foundation) today announced Bryan P. Schneider, M.D., as the recipient of the 2011 Advanced Clinical Research Award (ACRA) in Breast Cancer. Read more...

Posted on August 3, 2011
New Grant awarded to Malaz Ahmed Boustani, MD
Serum Biomarkers for Affective and Anxiety Disorders Following Acute Critical Illness

Malaz Ahmed Boustani, MD

Funding Source: NIMH.
Total Direct cost: $335,991
Duration: 2011-2013

In order to investigate the hypothesis that mainly glial alteration not neuronal damage is the underlying pathogenesis of late onset mood and anxiety disorders among older survivors of acute critical illness, we are conducting a six-month prospective cohort study of 200 older adults admitted to our local ICU for management of their acute illness. We will determine the presence of glial and neuronal pathology among these patients by measuring the serum level of S100B and neuron-specific enolase (NSE) within 48 hours and one week of their admission to the ICU and assess their depressive, anxiety and PTSD symptoms at three and six months after hospital discharge.

Dr. Renbarger Studies Vincristine

Jamie Renbarger, M.D., has made two new discoveries with a drug that was approved in 1963, opening the door to new knowledge that may further help children with cancer. Renbarger knew that vincristine -- which is widely used to treat cancers in children – led to side effects that varied considerably between patients. But why? In the lab, she discovered that two enzymes, CYP3A5 and CYP3A4, metabolize vincristine differently. CYP3A5, which is found in approximately 70 percent of African-Americans and 10 percent to 20 percent of Caucasians, metabolizes vincristine much more efficiently than CYP3A4. Knowing which enzymes to target, Renbarger next compared toxicity in Caucasians with African Americans who had Acute Lymphoblastic Leukemia. She showed that Caucasians developed side effects – such as jaw pain, loss of reflexes, and constipation -- with vincristine more often than African-Americans possibly due to the fact that the CYP3A5 enzyme is found in fewer Caucasians. Currently, Renbarger is enrolling 140 children with preB acute lymphoblastic leukemia to determine the optimal dosing of vincristine for pediatric patients, which may improve survival for young cancer patients. Renbarger's studies tie into the Best Pharmaceuticals for Children Act (BPCA), which established a process for studying drugs used in children with the goal of improving pediatric therapeutics. Vincristine has been identified as a priority drug to study. Because of the ongoing studies at the IU Simon Cancer Center, Renbarger and her team are generating data unlike any other research currently underway.

Research by Drs. Rolf Kreutz and David Flockhart is changing the way medications are prescribed.

Take a look in your medicine cabinet. How much do you know about the medications inside? In fact, how much does anyone really know about how the pills we ingest wend their way through our bodies and work their wonders? Not enough, it turns out. But a team of physicians and scientists at the Indiana University School of Medicine is taking a leading role in discovering more about how some commonly used drugs work and how an individual's genes affect the response. Full Article

Drs. Rolf Kreutz and David Flockhart